Cellectis Announces Groundbreaking in Vivo Proof of Concept Testing of Their Flagship UCART19 Product for Curative Therapy of Leukemia
7/8/2013 10:35:04 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
PARIS--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (Alternext: ALCLS), the genome engineering specialist, announced today the successful in vivo proof of concept testing of their flagship UCART19 product for curative therapy of leukemia. UCART19 is a revolutionary engineered T-cell product that leverages Cellectis’ core technologies in genome engineering. This standardized “off-the-shelf” therapy product is designed with a “chimeric antigen receptor” (CAR) to target and kill the most common types of acute and chronic leukemia and are engineered with Cellectis’ nucleases enabling the use of non-patient derived (allogeneic) T-cells. The results obtained show that the UCART19 product was able to eradicate human leukemia cells that had been transferred into mice, effectively curing the mice of tumors, and that the engineered T-cells performed as well as traditional CAR T-cells.
Help employers find you! Check out all the jobs and post your resume.
comments powered by